Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132924 | 1.00 | DNPH1 (0.53) | DNPH1P2RY2P2RY6IMPDH2IMPDH1 | |
| SCHEMBL18080319 | 0.91 | P2RY2 (0.61) | P2RY2P2RY6P2RY4 | |
| SCHEMBL18080091 | 0.90 | DNPH1 (0.54) | DNPH1P2RY2P2RY6IMPDH2IMPDH1 | |
| SCHEMBL18080071 | 0.86 | DNPH1 (0.54) | DNPH1P2RY2P2RY6IMPDH2IMPDH1 | |
| SCHEMBL21035550 | 0.86 | P2RY6 (0.39) | P2RY2P2RY6TAS1R3TAS1R1P2RY4 | |
| SCHEMBL18080089 | 0.85 | DNPH1 (0.54) | DNPH1P2RY2P2RY6TAS1R3TAS1R1 | |
| SCHEMBL18080073 | 0.84 | DNPH1 (0.52) | DNPH1P2RY2P2RY6IMPDH2IMPDH1 | |
| SCHEMBL15280219 | 0.84 | P2RY2 (0.39) | DNPH1P2RY2P2RY6IMPDH2IMPDH1 | |
| SCHEMBL17546719 | 0.84 | P2RY2 (0.39) | DNPH1P2RY2P2RY6IMPDH2IMPDH1 | |
| SCHEMBL16631345 | 0.84 | LMNA (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DNPH1 1736/4885P2RY2 2899/4885P2RY6 1545/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DNPH1 1736/4885P2RY2 2899/4885P2RY6 1545/4885 |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DNPH1 1736/4885P2RY2 2899/4885P2RY6 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.